504 related articles for article (PubMed ID: 7596415)
1. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
[TBL] [Abstract][Full Text] [Related]
2. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
3. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
4. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
Monji T; McCormack AL; Yates JR; Pious D
J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
[TBL] [Abstract][Full Text] [Related]
5. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
Belmares MP; Busch R; Mellins ED; McConnell HM
Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
[TBL] [Abstract][Full Text] [Related]
6. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
Neumann J; König A; Koch N
Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
[TBL] [Abstract][Full Text] [Related]
7. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
[TBL] [Abstract][Full Text] [Related]
8. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
9. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules.
Morris P; Shaman J; Attaya M; Amaya M; Goodman S; Bergman C; Monaco JJ; Mellins E
Nature; 1994 Apr; 368(6471):551-4. PubMed ID: 8139689
[TBL] [Abstract][Full Text] [Related]
10. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
[TBL] [Abstract][Full Text] [Related]
11. Presentation of abundant endogenous class II DR-restricted antigens by DM-negative B cell lines.
Kovats S; Whiteley PE; Concannon P; Rudensky AY; Blum JS
Eur J Immunol; 1997 Apr; 27(4):1014-21. PubMed ID: 9130658
[TBL] [Abstract][Full Text] [Related]
12. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
13. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
14. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases.
Lem L; Riethof DA; Scidmore-Carlson M; Griffiths GM; Hackstadt T; Brodsky FM
J Immunol; 1999 Jan; 162(1):523-32. PubMed ID: 9886429
[TBL] [Abstract][Full Text] [Related]
15. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
16. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
17. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells.
Albert LJ; Ghumman B; Watts TH
J Immunol; 1996 Sep; 157(6):2247-55. PubMed ID: 8805621
[TBL] [Abstract][Full Text] [Related]
18. Quantitative defect in staphylococcal enterotoxin A binding and presentation by HLA-DM-deficient T2.Ak cells corrected by transfection of HLA-DM genes.
Albert LJ; Denzin LK; Ghumman B; Bangia N; Cresswell P; Watts TH
Cell Immunol; 1998 Jan; 183(1):42-51. PubMed ID: 9578718
[TBL] [Abstract][Full Text] [Related]
19. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Chamuleau ME; Souwer Y; Van Ham SM; Zevenbergen A; Westers TM; Berkhof J; Meijer CJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Res; 2004 Aug; 64(16):5546-50. PubMed ID: 15313888
[TBL] [Abstract][Full Text] [Related]
20. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]